We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current HALO market cap is 6.89B. The company's latest EPS is USD 2.2133 and P/E is 24.46.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 216.03M | 230.04M | 195.88M | 231.35M | 290.08M |
| Operating Income | 88.28M | 101.04M | 95.54M | 117.24M | 163.2M |
| Net Income | 81.84M | 85.39M | 76.82M | 93.25M | 137.01M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 195.99M | 267.59M | 443.31M | 660.12M | 829.25M |
| Operating Income | -67.61M | 144.26M | 275.9M | 267.53M | 337.57M |
| Net Income | -72.24M | 129.09M | 402.71M | 202.13M | 281.59M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.89B | 1.73B | 1.84B | 1.97B | 2.12B |
| Total Liabilities | 1.64B | 1.65B | 1.66B | 1.68B | 1.67B |
| Total Equity | 249.18M | 83.81M | 177.81M | 289.42M | 452.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 565.87M | 579.92M | 1.1B | 1.84B | 1.73B |
| Total Liabilities | 474.11M | 428.88M | 907.48M | 1.67B | 1.65B |
| Total Equity | 91.77M | 151.05M | 196.95M | 169.8M | 83.81M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 286.22M | 388.57M | 129.43M | 185.22M | 300.6M |
| Investing | -88.62M | -96.91M | -82.68M | -124.72M | -292.2M |
| Financing | -158.07M | -407.99M | -489k | 8.99M | 27.55M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -85.42M | 55.45M | 299.44M | 240.11M | 388.57M |
| Investing | -5.55M | 78.35M | -406.29M | -487.01M | -96.91M |
| Financing | 153.22M | -106.28M | 77.87M | 362.37M | -407.99M |
| Market Cap | 6.89B |
| Price to Earnings Ratio | 24.46 |
| Price to Sales Ratio | 8.31 |
| Price to Cash Ratio | 58.19 |
| Price to Book Ratio | 82.19 |
| Dividend Yield | - |
| Shares Outstanding | 127.23M |
| Average Volume (1 week) | 2.08M |
| Average Volume (1 Month) | 1.62M |
| 52 Week Change | 58.49% |
| 52 Week High | 65.5327 |
| 52 Week Low | 33.15 |
| Spread (Intraday) | 1.2 (2.18%) |
| Company Name | Halozyme Therapeutics Incorporated |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.halozyme.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
